Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryLinklaters makes major US M&A hire as Wachtell partner departures continueLaw firmsKate Peacock10 Sep 2026Trading Places: Weil makes New York hire as Paul Weiss picks up Kirkland funds partnerLaw firmsKate Peacock9 Sep 2026EMEA’s most recommended law firms revealed by Legal 500 client researchLaw firmsAmy Ulliott8 Sep 2026Former Goodwin lawyer pleads not guilty to charges of insider tradingLaw firmsWill Lewallen11 Sep 2026Full details – the six M&A partners set to leave Weil for CravathLaw firmsKate Peacock11 Sep 2026Freshfields doubles down on US with hires from Weil and CravathLaw firmsWill Lewallen10 Sep 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022